# Attovia Therapeutics, Inc. — capital_raise/public_offering [completed]
Source: SEC API (secapi.ai) · situation sit_8366128ed16aafa92d5f · retrieved 2026-08-11T15:51:35.774Z

## Overview
Attovia Therapeutics is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, leveraging its proprietary ATTOBODY biologics platform to create monospecific and multispecific therapeutics; its lead candidate ATTO-1310 targets interleukin-31 (IL-31) for chronic pruritic diseases and completed Phase 1 dosing in the fi…

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its ATTOBODY platform, completed its initial public offering of 17,000,000 shares of common stock at $17.00 per share, generating gross proceeds of $289,000,000. Net proceeds to the company, after underwriting discounts and commissions of $20,230,000, were approximately $268,770,000. The company's common stock was approved for listing on the Nasdaq Global Market under the symbol "ATTO." The underwriters were granted a 30-day option to purchase up to an additional 2,550,000 shares to cover over-allotments, and shares were expected to be delivered to purchasers on August 6, 2026.

## Terms
- Deal value: $289.0M · Consideration: cash · Price/share: $17

## Key dates
- Announced 2026-07-14 · Completed 2026-08-06

## Timeline
- 2026-07-14 · S-1 (0001193125-26-303256): S-1 - Attovia Therapeutics, Inc. — *Attovia Therapeutics is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its ATTOBODY biparatopic biologics platform, which it in-licensed from Alamar Biosciences.* Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its ATTOBODY platform, is conducting an initial public offering of common stock. The company has applied to list on Nasdaq under the symbol "ATTO." The offering price range and share count are to be determined. Attovia's lead candidate, ATTO-1310, an IL-31-targeting therapeutic, completed dosing in a Phase 1 trial in healthy volunteers and patients in Q1 2026. ATTO-2306, a bispecific targeting IL-13 and IL-31, is in IND-enabling studies with Phase 1 expected in H1 2027. ATTO-1091, a trispecific targeting TL1A, IL-23, and integrin α4β7 for IBD, is also in IND-enabling studies with Phase 1 expected in H1 2027.
  https://www.sec.gov/Archives/edgar/data/2058707/0001193125-26-303256.txt
- 2026-08-04 · S-1/A (0001193125-26-331510): S-1/A - Attovia Therapeutics, Inc. — *Attovia Therapeutics is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its ATTOBODY biparatopic biologics platform, with lead candidate ATTO-1310 (targeting IL-31 for chronic pruritic diseases) currently in Phase 1 clinical trials, ATTO-2306 (targeting IL-13 and IL-31 for atopic dermatitis) in IND-enabling studies, and ATTO…* Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its ATTOBODY platform, is conducting an initial public offering of 17,000,000 shares of common stock at an estimated price of $17.00 per share. The company has applied to list its common stock on the Nasdaq Global Market under the symbol "ATTO." Underwriters have been granted an option to purchase up to an additional 2,550,000 shares to cover over-allotments. Based on the estimated offering price and after deducting underwriting discounts and commissions and estimated offering expenses, the company expects net proceeds of approximately $265.1 million (or approximately $305.4 million if the underwriters exercise their over-allotment option in full).
  https://www.sec.gov/Archives/edgar/data/2058707/0001193125-26-331510.txt
- 2026-08-05 · 424B4 (0001193125-26-334997): 424B4 - Attovia Therapeutics, Inc. — *Attovia Therapeutics is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, leveraging its proprietary ATTOBODY biologics platform to create monospecific and multispecific therapeutics; its lead candidate ATTO-1310 targets interleukin-31 (IL-31) for chronic pruritic diseases and completed Phase 1 dosing in the fi…* Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its ATTOBODY platform, completed its initial public offering of 17,000,000 shares of common stock at $17.00 per share, generating gross proceeds of $289,000,000. Net proceeds to the company, after underwriting discounts and commissions of $20,230,000, were approximately $268,770,000. The company's common stock was approved for listing on the Nasdaq Global Market under the symbol "ATTO." The underwriters were granted a 30-day option to purchase up to an additional 2,550,000 shares to cover over-allotments, and shares were expected to be delivered to purchasers on August 6, 2026.
  https://www.sec.gov/Archives/edgar/data/2058707/0001193125-26-334997.txt

## Citations
- 0001193125-26-303256 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526303256
- 0001193125-26-331510 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526331510
- 0001193125-26-334997 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526334997